Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abivax SA ( (FR:ABVX) ) has provided an announcement.
Abivax SA announced the presentation of seven scientific abstracts on Obefazimod at the 20th annual congress of the European Crohn’s and Colitis Organization in 2025. These presentations, including both oral and poster sessions, highlight ongoing research on the efficacy and tolerance of Obefazimod in ulcerative colitis patients, along with insights into long-term treatment patterns and quality of life impacts. This significant scientific engagement underscores Abivax’s commitment to advancing therapeutic options in the inflammatory bowel disease space, potentially enhancing its industry positioning and offering promising implications for stakeholders.
More about Abivax SA
Abivax SA is a clinical-stage biotechnology company focused on developing innovative treatments for chronic inflammatory diseases. The company is engaged in the clinical development of Obefazimod, an experimental small molecule drug aimed at treating active, moderate to severe ulcerative colitis.
YTD Price Performance: -8.57%
Average Trading Volume: 810
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €392.8M
See more insights into ABVX stock on TipRanks’ Stock Analysis page.
